Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase I Study of GPC3 Targeted CAR-T Cell Therapy in Advanced GPC3 Expressing Solid Tumor Malignancies

NCT05003895 is registered in ClinicalTrials.gov with National Cancer Institute (NCI) as lead sponsor.

NCT NCT05003895
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05003895 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase I Study of GPC3 Targeted CAR-T Cell Therapy in Advanced GPC3 Expressing Solid Tumor Malignancies
Lead sponsor
National Cancer Institute (NCI)
Phase
Phase 1
Overall status
Recruiting
Start date
December 8, 2021
Completion date
December 31, 2027
Enrollment
38 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

hepatocellular cancer, hepatocellular carcinoma, metastatic hepatocellular carcinoma